Maze Therapeutics Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria (PKU) and chronic kidney disease (CKD). Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD). The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.